Maturitas
Volume 55, Issue 2 , Pages 156-161 , 20 September 2006

The safety of tibolone in epithelial ovarian cancer patients

Received 8 August 2005 ,Revised 20 January 2006 ,Accepted 25 January 2006.

References 

  1. 2002 Annual report of the Korea central cancer registry (2002.1–2002.12). Republic of Korea: Korea Central Cancer Registry, Ministry of Health and Welfare; 2003.
  2. Pecorelli S, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. Annual report on the results of treatment of gynecological cancer, vol 23. International Federation of Gynecology and Obstetrics. J Epidemiol Biostat. 1998;3:75–102
  3. Berek JS, Hacker NF. Epithelial ovarian cancer—practical gynecologic oncology. 3rd ed.. Philadelphia: Lippincott Williams & Wilkins; 2005;
  4. Trimble EL, Kosary CA, Cornelison TL, et al. Improved survival for women ovarian cancer. Proc Soc Gynecol Oncol. 1999;(Abstract 136)
  5. Staging Announcement: FIGO Cancer Committee . Gynecol Oncol. 1986;25:383
  6. Eeles RA, Tan S, Wiltshaw E, et al. Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ. 1991;302:259–262
  7. Guidozzi F, Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer. 1999;86:1013–1018
  8. Urisc-Vrscaj M, Bebar S, Primic Zakelij M. Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. Menopause. 2001;8:70–75
  9. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancer in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol. 1992;136:1184–1203
  10. Grag PP, Kerlikowske K, Subak L, et al. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol. 1998;92:472–479
  11. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynecol. 1990;97:1080–1086
  12. Modelska K, Cummings S. Tibolone for postmenopausal women: systemic review of randomized trials. J Clin Endocrinol Metab. 1993;7:183–202
  13. Gruber CJ, Tschugguel W, Schneeberger C, et al. Production and actions of estrogens. N Engl J Med. 2002;31:340–352
  14. Colacurci N, Mele D, De Franciscis P, et al. Effects of tibolone on the breast. Eur J Obstet Gynecol Reprod Biol. 1998;80:235–238
  15. Kloosterboer HJ, Schoonen WG, Deckers GH, et al. Effects of progestagens and Org OD14 in in vitro and in vivo tumor models. J Steroid Biochem Mol Biol. 1994;49:311–318
  16. Gompel A, Siromachkova M, Lombet A, et al. Tibolone actions on normal and breast cancer cells. Eur J Cancer. 2000;36:76–77

PII: S0378-5122(06)00056-9

doi: 10.1016/j.maturitas.2006.01.010

Maturitas
Volume 55, Issue 2 , Pages 156-161 , 20 September 2006

Article Tools

* Image Usage & Resolution